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Abstract 
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the difficulties of 
establishing the credibility of trial-based and modeled claims for therapy interventions. Claims for interventions in the management of 
chronic pain are no exception. To meet this challenge, the Chronic Pain Management Registry (CPMR) has been designed to provide an 
evidence base for physician practices and health care decision makers to evaluate the impact of pain management interventions. The 
purpose of this commentary is to detail the development, structure and content of the CPMR in two versions: (i) a patient response 
version and (ii) a combined patient/provider response version. The CPMR has a potentially critical role to play in providing a framework 
for the effective auditing of practice compliance in the prescribing and monitoring of opioids in the management of chronic pain. The 
CPMR tracks, with on-line input from the patient and the treating physician, the process and outcomes of therapy interventions. These 
reports cover the overall pain experience of patients as well as pain intensity and functional status by eleven specific pain locations, 
covering both pharmacological and non-pharmacological interventions. Prior to each practice visit patients complete reports which are 
entered to the CPMR with a summary transmitted to the physician practice. Over time, these reports track the cumulative response to 
therapy as well as the perception of the patients as to whether or not the therapy has led to any substantive improvement in activity 
limitations, symptoms and quality of life. A particular focus of the CPMR is on monitoring and evaluating the experience with, and 
impact of opioid medications, to include the effectiveness of opioid formulations on reducing pain intensity and improving functional 
status, including an intensive assessment of the potential for and experience of opioid substance abuse for individual patients. The 
CPMR can also support monthly reports to the practice to summarize patient throughput, the response to care by target pain patients 
and profiles of opioid use and abuse. The CPMR can be customized to meet the needs of individual practices. 
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Introduction 
The choice of therapy option and associated outcomes for 
patients experiencing chronic pain has received increasing 
attention over the past decade, with a major focus of public 
policy on the blanket use, potential abuse and the actual clinical 
efficacy of opioid medications. At the same time, there has 
been increased attention given to the quality of care and 
outcomes of health care interventions in chronic pain and a 
range of other disease states. This is seen in the emphasis on 
how value in health care is paid for and coordinated with the 
shift toward increased collaboration, outcome-based payments 
and new benefit designs 1. As an example under the Patient 
Protection and Affordable Care Act, the Centers for Medicare 
and Medicaid Services (CMS) have initiated a number of 
programs and underwritten a range of quality metrics to meet 
the three aims of better care, smarter spending, and healthier 
people. In the Medicare population, for example, the Merit 
Based Incentive Payment System  
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(MIPS) offers substantial financial incentives for healthcare 
providers to report: (i) a range of quality metrics, (ii) activities 
to support comprehensive healthcare information and (iii)  
care improvement activities. There has also been a major 
expansion in the number of reportable and billable Current 
Procedure Terminology (CPT) codes (e.g., CPT 96127 Brief 
Emotional/Behavioral Assessment) designed to support more 
focused patient assessment and to facilitate outcomes tracking. 
Appropriately used, these promise a financial return to 
physician practices to meet the increased demands for greater 
efficiency in resource allocation and measured greater 
effectiveness in the provision of health care.  
 
The CPMR is available in two versions: (i) a patient only 
response platform and (ii) a patient and provider response 
platform. These options recognize that pain practices may not 
have the resources or may not be willing in the first instance to 
commit to a registry where data are captured from both 
patients and physician practices. 
 
Both versions of the CPMR generate summary reports on 
individual patients to support ongoing clinical assessments of 
response to therapy as well as customized practice 
management reports for target patient groups. At the same 
time the adoption of a CPMR by a specialist pain practice or 
primary care group provides an interface to a proposed 
companion medical marijuana dispensary registry. This links 
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provider certification of a patient for medical marijuana use to 
outcomes reported by patients who have enrolled in a medical 
marijuana dispensary. Credible evidence on outcomes from a 
cannabis dispensary registry is important as it has the potential 
to provide justification for switching patients from opioids in 
the medium and long-term management of chronic pain. It is 
worth emphasizing that severe pain is the single most 
important condition reported to dispensaries, accounting for 
75-85% of clients. 
 
From Process to Outcome 
A critical element in practice-based performance, envisaged in 
the increased focus by agencies such as CMS in switching from 
process to outcome measures, is to track patients over the 
course of their treatment. It is becoming incumbent upon 
physician practices and health care systems not only to track 
patients over the course of their disease but to ensure that, 
wherever possible, tracking metrics utilize validated patient 
reported outcomes (PRO) instruments in their management 
and evaluation of the ongoing patient response to therapy. 
 
The increased emphasis on tracking patients reflects a long-
standing concern with the evidentiary standards for clinical 
decisions in chronic pain treatment practice. This concern 
reflects, not only the limited evidence for the medium and long-
term impact of treatment interventions but the credibility of 
the published evidence. The latest CDC Guidelines for 
Prescribing Opioids for Chronic Pain point out that evidence on 
long-term opioid therapy for chronic pain outside of end-of-life 
care remains limited, with insufficient evidence to determine 
long-term benefits versus no opioid therapy 2.  Although clinical 
trial data would suggest that risk for serious harms appear to 
be dose dependent, the evidence is typically short-term with 
most trials only reporting outcomes for 12 weeks or less. At 
best, the evidence would suggest that opioids are only 
moderately effective for pain relief and with small benefits for 
functional outcomes. This criticism applies with equal force to 
established opioid formulations as well as to the abuse 
deterrent opioid formulations that are entering the market 
place. Formulary committees cannot judge the competing 
merits claimed for abuse deterrent formulations in the absence 
of credible evidence, both from randomized clinical trials (RCTs) 
as well as practice based observational studies.  
 
In the absence of adequate evidence, the risk is that a high 
percentage of patients will discontinue opioid use because of 
lack of efficacy and adverse events. If this is the case then the 
question might be raised as to the advisability of introducing 
patients to these medications in the first place or at least 
managing these patients more intensively. At the same time, 
blanket promotion and uninformed use of opioids and other 
controlled substances in chronic pain, all too often endorsed by 
manufacturers, puts patients at avoidable (in retrospect) risk of 
abuse, dependency and utilization of more high risk illegal 
substances. While botanical cannabis provided through a 
dispensary may offer a viable option to opioids as a mainstay of 
chronic pain management, what is missing is the evidence base 
for  botanical cannabis  to  support  physician  decision  making.  
   
Concerns with the limited evidence for medium and long-term 
outcomes in chronic pain are not restricted to pharmacological 
interventions. A similar dearth of evidence applies to a number 
of non-pharmacological interventions. In the case of 
radiofrequency ablation, for example, the most recent 
systematic review for sacroiliac joint interventions pointed to 
the variable quality of the evidence, including inconsistencies in 
diagnostic accuracy, small sample sizes to support study claims 
and a lack of claims replication.  Similar concerns apply to the 
evidence for cooled radiofrequency ablations, programmable 
pumps, percutaneous vertebroplasty and kyphoplasty 3 4 5 6 7 8 
. Even where single studies claim medium and even long-term 
benefits, the focus is typically on pain relief with little attention 
(if any) directed to the functional status of patients by pain 
location.  
 
A further concern, and this applies to both pharmacological and 
non-pharmacological pain interventions, is heterogeneity in 
response to pain interventions and how this response varies 
over time. If, for example, nerve ablation is seen as initially 
preferable to drug therapy, the question still remains as to 
whether patients who achieve only a partial response require 
supplementary pharmacological treatment to reduce pain and 
achieve functional improvement. At the same time, over the 
medium to long-term the option may be between further nerve 
ablation or switching to a pharmacological therapy including 
botanical cannabis. 
 
Unfortunately, few physician practices are equipped to monitor 
and report patient outcomes, as well as reporting at a practice 
level on the response to therapy by target patient groups. 
Electronic medical records (EMRs) are not designed to report 
on cumulative response to therapy.. More to the point: EMRs 
are deficient in their inability to provide and interpret patient 
reported outcomes (PROs) from validated instruments and to 
track these over time in terms of a clinical impact. This is of 
importance in the treatment of chronic pain where the clinical 
evidence for long term benefit of competing interventions is 
limited  in terms of both pain intensity and functional status by 
pain location. 
 
At the same time, few pain practices are equipped to meet 
recommendations for effective opioid prescribing, to justify the 
introduction of opioids as a therapy option and to support the 
ongoing medium and long-term utilization of opioids. While 
there are guideline recommendations in place to support the 
prescription of opioids in the more effective treatment of non-
cancer pain, their application appears limited. A major impetus 
in the development of the CPMR has been to provide a 
framework for the more effective management of chronic pain 
and the prescribing of opioids and opioid substitutes. Concerns 
with physician and practice compliance were at the forefront in 
platform design with the role of the platform, particularly given 
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concerns with potential legal liability, of providing a robust 
audit trial to track the interactions between the patient and the 
treating physician. The recommendations of the American 
Society of Interventional Pain Physicians (ASIPP) were of 
particular assistance 9.  
 
Customization 
Apart from the option of a patient as opposed to a provider-
patient version of the CPMR, the registry structure retains the 
flexibility for customization to meet the needs of pain practices. 
Additional items can be included (e.g., specific comorbidities, 
specific line items) with on-line screen modifications, to include 
modifications to the registry data dictionary. If elements of the 
registry are felt to involve an undue burden on patients and/or 
providers as respondents, these can also be modified without 
putting the basic integrity of the registry data collection and 
reporting at risk. 
 
Patient Compliance and Opioid Prescribing 
 Establishing an audit trail as part of a chronic pain management 
platform allows both the physician practice and other 
interested parties to assess therapy decisions in providing an 
evidence base that physicians can point to in support of those 
decisions.  The proposed registry is ideally suited to creating 
audit trails. Given standards in place for tracking and 
monitoring the prescribing of opioids, the CPMR is ideally suited 
to support third party audits of physician practice. The CPMR 
provides a baseline profile of the patient’s pain status, prior 
experience of opioids, attitudes to medications and the 
likelihood of aberrant medication behavior to support a 
decision to introduce and monitor opioid use.  The CPMR tracks 
the response to therapy, in terms of both clinical response and 
the patent’s belief in the efficacy of the therapy choice, 
together with the patient reporting aberrant medication 
behaviors.  
 
At the same time the patient and physician practice version 
documents therapy changes, adverse events together with 
reasons for tapering and/or discontinuation of therapy. The 
CPMR documents whether or not alternative to opioid 
medication have been considered and the reasons for a patient 
not scheduling further visits.  
 
Credibility of Medical Marijuana 
The evidence base for the impact of medical marijuana, 
prescription marijuana products as well as botanical cannabis, 
is both fragmented and incomplete for the range of conditions 
that are typically treated under patient certification. Previous 
commentaries have pointed to the need for a more credible 
base, proposing that dispensaries establish registries to track 
patients 10 11 12. If we accept that dispensaries have a duty of 
care to their patients, then establishing a registry should 
establish links to the providers with feedback on response to 
the choice of cannabis formulation and the delivery regimen. 
Although guidelines are only in their early stages, the consensus 
view appears to be that patients should start with a high CBD 
(cannabidiol) and low THC (tetrahydrocannabinol) ratio and 
titrate to an effective dose. Ideally, it is argued, THC should be 
avoided altogether due to is psychoactive properties with 
patients only on a CBD regimen, which may include other 
potentially beneficial non-THC related cannabinoids. Whether 
these recommendations are sustainable is an open question.  
 
With the passing of the 2018 Farm Bill and the legalization of 
hemp the door has opened (at least partially) for the production 
of hemp-based products and extending hemp research by 
including it under the Critical Agricultural Materials Act. This 
does not mean that hemp-based CBD is legalized although it has 
been removed from its schedule 1 status under the Controlled 
Substances Act. The legislation creates exceptions to its status. 
Any cannabinoid derived from hemp, including vaporizing CBD 
oils for potential pain relief, must be produced in accordance 
with the legislative requirements, including state regulations. 
There are, in fact, hemp-based cannabinoid products already 
produced in certain states for consumption within that state. 
 
The (constrained) legalization of hemp-CBD and the potential 
for a more widespread utilization of derivative products such as 
hemp CBD oil, means that physicians will have access to a range 
of products that are potentially beneficial in the treatment of 
severe and chronic pain. The stumbling block is still, however, 
the evidence base. Hence the case for a chronic pain registry to 
provide the framework for tracking the use of hemp-derived 
cannabinoid products. At present, under medical marijuana 
legislation these would be provided through a licensed 
dispensary. This opens the possibility of the registry linking to a 
provider to support the auditing of therapy response.  
 
Unfortunately, until new compounds are approved that allow 
us to put opioids to one side physicians are faced with the 
decision to balance their risks and benefits; a decision which is 
made all the more difficult by the absence of evidence on the 
long-term impact of opioids and cannabinoids on both pain 
levels and functional status. At the same time, physicians have 
to be aware that blanket denials for opioid utilization are 
becoming more common. The CPMR attempts to provide a 
middle ground. As well as providing an evidence base that 
physicians may utilize to defend opioid and cannabinoid 
utilization decisions and meet compliance standards, the CPMR 
provides feedback to the physician to monitor outcomes, 
including those from cannabinoids. The CPMR, therefore, not 
only provides evidence to support an initial prescribing decision 
based on medical necessity but continues to provide evidence 
to support (or deny) continued opioid prescribing. Access to 
documentation to support prescribing can also support appeals 
where opioid prescribing has been denied. This provides 
additional flexibility in challenging third-party decisions when 
the treating physician has determined and can justify a 
particular therapy choice on grounds of medical necessity. 
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The Evidence Base 
There are a number of features of chronic pain populations that 
support the need for a registry. A recent study by Romanelli et 
al illustrates the heterogeneous characteristics of chronic pain 
populations13. Utilizing the Sutter Health EMR database in a 
cross section study for 2012 the analysis points to the 
importance of disaggregating chronic pain patients by pain 
type, identifying the number and types of pain conditions 
reported (with only 40% reporting one pain condition). At the 
same time account should be taken of the presence of 
comorbidities with only 28% of pain patients reporting no 
comorbidities while 21% report with 4 or more comorbidities 
the distribution of pain types.  
 
Improving the quality of care can only occur if there is feedback 
to health care providers on the outcomes of treatment 
interventions within a clinically meaningful timeframe14.   There 
is all too often a major disconnect between claims made for 
new products and devices to formulary committees and the 
ability of healthcare systems to validate such claims.  
Supporting feedback involves judging the credibility of claims 
made for pharmaceutical products and devices, evaluating 
these claims in treatment practice and providing the 
opportunity, as noted above, for claims replication across 
treating environments. This is achieved in the CPMR by 
requiring physician practices to detail reasons for therapy 
discontinuation, to include specific reasons for the 
discontinuation, by either the physician or the patient, of opioid 
therapy. 
 
Outcomes claims should be judged in terms of clinical markers. 
The Food and Drug Administration (FDA) recognizes that in drug 
approvals evidence is required of a favorable benefit defined in 
terms of how a patient feels, functions and survives. It is 
important, therefore, as part of quality metrics to capture, via 
validated patient reported outcomes (PRO) instruments both 
response to therapy as well as measures that reflect symptoms 
and quality of life. This is addressed in the CPMR by asking 
patients, not only how their symptoms or comorbidities have 
improved (or at least been addressed) during the course of 
treatment but, utilizing the Patients’ Global Impression of 
Change (PGIC) scale, how they would describe the change (if 
any) in activity limitations, symptoms, emotions and overall 
quality of life related to their painful condition since the 
beginning of their therapy.15 This question is asked at each 
follow-up visit to the practice. The seven responses allowed 
range from “No change (or condition got worse)”, through 
“Somewhat better, but the change has not made any real 
difference” to ‘A great deal better, and a considerable 
improvement that has made all the difference”. Care needs to 
be taken, however, in not focusing exclusively on the PGIC 
responses16.  
The outcomes covered by the CPMR are also consistent with 
those proposed as core outcomes for chronic pain clinical trials 
by the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT)17. The six core 
IMMPACT domains are outcomes representing: (i) pain, (ii) 
physical functioning; (iii) emotional functioning; (iv) participant 
ratings of improvement and satisfaction with treatment; (v) 
symptoms and adverse events; and (vi) participant disposition 
(e.g., persistence/adherence). These domains are all reported 
in the CPMR.  
 
Chronic Pain Management Platform  
The CPMR incorporates 18 validated PRO instruments to 
capture response to therapy and comorbid behaviors. The 
CPMR captures from each patient: 
• demographic and socio-economic characteristics 
• overall pain experience 
• prior chronic pain and the likelihood of continuing 
chronic pain 
• pain experience and functional status for 13 designated 
pain locations 
• medication utilization 
• assessment of the likelihood of neuropathic pain 
• indicators for possible fibromyalgia 
• attitudes to pain medications 
• opioid utilization 
• risk for medication aberrant behavior 
• self-reported aberrant medication behavior 
• symptoms: fatigue, depression, anxiety, sleep 
• constipation  
• satisfaction with care 
At the same time, the CPMR captures, in the provider version, 
the following as inputs from the practice:  
• cause of pain (surgery, trauma) 
• medication utilization 
• ICD-10-CM diagnoses [CMS 1500] 
• CPT (current procedures) [CMS 1500] 
• adverse events [ICD-10-CM codes] 
• specialty referrals 
• urine test 
• opioid use and consent 
• medical marijuana use 
• alternative therapy options 
• reasons for therapy discontinuation 
Combining these data elements, the CPMR creates a structured 
profile of therapy choice and therapy impact in chronic pain. 
This offers a unique insight into the clinical effectiveness of 
therapy in real-time with providers appraised at each visit 
whether patients are responding to therapy and whether the 
clinical response meets standards for a clinically meaningful 
improvement. At the same time, as detailed below, the CPMR 
allows the physician to focus on the choice of opioid therapy, 
the particular formulation selected and the response to 
therapy. Options for therapy switching are reported together 
with reasons for discontinuation.  
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CPMR Forms 
When a new patient joins a practice, the patient is typically 
asked to complete, either on-line through the practice CPMR 
portal or in paper form (downloaded from the CPMR), a series 
of forms. If paper forms are completed, these would be brought 
to the provider on first visit. If the CPMR is used, the selection 
of forms and the procedure for completion will be agreed with 
the practice. The CPMR includes, as a default, the following 
forms:  
• Patient personal information (contact details, 
pharmacy, insurance, workers compensation, injury 
claims) 
• Consent for treatment 
• Privacy notice: Use and disclosure of medical 
information 
• Practice financial policy (billing, insurance cover) 
• Current prescription medications and over the 
counter products 
• Authorization for use/disclosure of protected health 
information 
As well, when required, the registry also includes two additional 
forms specific to chronic pain interventions. The first is a 
‘Patient Agreement: Pain Treatment with Opioid or Controlled 
Substance Medications’ form that sets out the responsibilities 
of the patient and provider if opioids or other controlled 
substances are prescribed for long-term treatment of chronic 
pain. The second form is a ‘Consent to Medical/Surgical Office 
Procedure’ that may be part of the chronic pain treatment 
strategy. All forms require a patient signature. If a practice 
wishes to substitute or add its own forms this can be 
accommodated as part of a practice customization. Although 
the CPMR provides ‘generic’ forms, the practice may ask for its 
own forms to be substituted with additional forms if necessary.  
 
Patient CPMR Version 
Information requested from the patient and completed on line 
covers: 
• Patient Initial Visit Report 
• Patient Follow-up Visit Reports -  follow-up reports 
for all subsequent practice visits (or requests for 
follow-up information in the absence of a practice 
visit) 
• Patient Satisfaction Initial Visit Report (including pain 
management section) 
• Patient Satisfaction Follow-up Visit Reports  
On receipt of the initial visit report from the patient and the 
follow-up reports for all subsequent practice visits, a summary 
report is generated and transmitted directly to the pain practice 
so that it is available to the treating physician prior to the 
patient encounter. The follow-up visit summary reports link to 
the initial pain and functional status report to detail changes in 
pain and functional status since the first visit. This is supported 
by the patient’s responses to the PGIC scale.  
 
Patient Initial Visit Report 
The Patient Initial Visit Report focuses on five areas. These are: 
(i) demographic and socio-economic characteristics; (ii) overall 
pain experience; (iii) pain and functional status by pain location; 
(iv) attitudes and risks in medication utilization; and (v) 
symptoms and co-morbidities. 
 
Evaluating outcomes of therapy, whether at the individual 
patient or the targeted patient group level, should take account 
of the impact of potential confounding factors. These factors 
may impact the ongoing experience of pain as well as the 
response of patients to therapy. In the CPMR the more 
prevalent comorbidities for non-cancer pain are captured in the 
validated instruments that capture the presence of fatigue, 
depression, anxiety, constipation and sleep. At the same time 
there are patient characteristics which should be considered. In 
particular: gender, race and ethnicity, employment status and 
education.  
 
Demographic and Socioeconomic Characteristics 
There is a substantive body of literature regarding sex 
difference in pain 18. The evidence points to females reporting 
a higher prevalence and severity, together with increased pain 
sensitivity and risk for pain. At the same time, females differ in 
their response to pain treatment and in their perception of 
pain, although the evidence for the consistency of response to 
both pharmacological and non-pharmacological interventions 
is mixed. In the case of opioids, for example, the evidence 
suggests greater morphine analgesia for women and with 
greater analgesia than men for mixed action opioids. There is 
also evidence for gender biases in pain treatment. 
 
Ethnicity is also a potential confounding factor in evaluating 
response to therapy. While there is no evidence that Hispanic 
and African-American status can impact response to therapy in 
pain management ethnicity may be a proxy for access to and 
compliance with care 19 20.   
 
Current employment status and the reasons for not working are 
also of interest in pain management. Of particular interest is the 
impact of pain on employment status and, if part of a pain 
management plan’s objectives, the success of an intervention 
in returning a patient to work. 
 
Educational attainment has long been recognized as a risk 
factor for chronic pain. Dionne et al, in a review of the relation 
between educational status and back pain published in 2001, 
concluded that the evidence suggests that rather than an 
association with onset, lower educational status is associated 
with longer duration and/or higher recurrence 21. The likelihood 
of more disabling back pain is possibly explained by variations 
in behavioral and environmental risk factors, poor overall 
health, differences in occupational factors, differences in access 
and/or utilization and adaptation to stress.  A Norwegian study, 
for example, found that each additional year of formal 
education was associated with a lower risk of a disability 
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pension, while occupational class, working conditions and 
individual lifestyle reduced the effect of education 22 .  Even so, 
there was still a ‘strong and unexplained effect of education on 
back pain disability pensioning, which is not mediated by 
occupational class, working conditions or individual lifestyle’. 
These issues can be explored with data from the CPMR. 
 
Overall Pain Experience 
In large part because of the likelihood that a proportion of 
patients may report pain at more than one location together 
with the difficulty of establishing prior experience with pain 
levels and pain locations, the CPMR adopts a two stage 
approach in evaluating baseline pain experience at the initial 
visit.  
 
In the first stage, patients are asked to detail their overall 
current pain experience together with their long-term 
experience of pain together and an assessment of their 
likelihood of their continuing to experience chronic pain. 
Current pain experience is defined in terms of (i) current pain 
on a standard visual analogue scale (VAS) where 0 = no pain and 
10 = pain as bad as it could be; (ii) worst pain (VAS scale) in past 
two weeks; and (iii) average pain (VAS scale) over the past two 
weeks. These scores are combined to give a ‘pain intensity’ 
score. Patients then report their prior experience of chronic 
pain and the impact of their pain experience in the past six 
months on their activity status utilizing the validated Chronic 
Grade Pain Scale (CGPS) instrument23. This yields two 
categories of pain and disability and two categories of disability 
and its limiting effects. Finally, in this section, the algorithm 
proposed by Von Korff and Dunn is applied, with supplementary 
questions, to yield a risk score for the likelihood of continuing 
chronic pain 24.    
 
Pain and Functional Status by Pain Location 
In the second stage, the focus is on pain intensity and functional 
status by body location. The CPMR identifies 13 pain locations 
and uses, where feasible, validated instruments to assess 
baseline pain intensity and functional status, tracking this over 
the course of treatment.  In some cases the instrument only 
identifies functional status and, where this occurs, 
supplementary questions to measure pain intensity are 
included. This format, as detailed below, is repeated for all 
subsequent visits (or reports) to create a tracking of patient 
response to therapy. 
 
Table 1 details the 13 pain locations and the validated 
instrument that is proposed to assess functional status and, 
unless supplemented by a pain intensity score, the pain level 
reported. Scores are presented in the patient summary and 
sent to the provider both for the aggregate score as well as 
scores categorized to grade levels and subscales. Patients 
indicate which pain location (or locations) is (are) appropriate 
and a drop down screen is presented for the instrument 
completion together with supplemental pain intensity 
questions if required. As patients are asked to respond to their 
nominated pain locations at each subsequent visit, the 
instruments and supplemental pain questions create a real-
time profile of response to therapy for both pain intensity and 
functionality. 
 
The CPMR also addresses the question of the likelihood of the 
patient experiencing neuropathic pain. Although a clinical 
diagnosis for neuropathic pain is the ‘gold standard’ a number 
of instruments have been proposed as symptom-based 
screening questionnaires for neuropathic pain. These 
instruments include the Self-completed Douleur 
Neuropathique 4 (S-DN4) 25 , the ID-Pain 26, the pain detect 
questionnaire (PDQ) 27 and the Self-completed Leeds 
Assessment of  Neuropathic Symptoms and Signs (S-LANSS)28.    
For the purpose of the CPMR, the instrument selected was the 
ID-Pain with 6 sensory description items. The ID-Pain is short, it 
does not involve any patient self-examination and 
psychometrically it performs as well as the S-DN4 and PDG, and 
better than the S-LANSS 29.  Similarly, in the case of possible 
fibromyalgia, the patient is asked to report on the pain 
experience across multiple locations. Again this is only 
indicative and is not a substitute for a clinical assessment.  
 
It is worth emphasizing again that the client has the option of 
customizing their version of the CPMR to include alternative 
pain and functional status instruments. The Oswestry scale 
could, for example, be substituted for the Roland Morris 
Disability instrument scale with alternative instruments for 
head pain and lower extremity pain. If substitutions are 
required then it is the responsibility of the client to obtain the 
necessary permissions and pay any fees if not in the public 
domain.   
 
In the case of scores for hip pain, leg pain and foot or heel pain 
the assessment is in terms of (i) response to an item list (13 ) to 
give assessment of status by item but no overall score and (ii) 
pain intensity at present time, worst in previous two weeks and 
average over past two weeks. Again, there is the option for a 
client to choose a specific measures of pain and functional 
status for hip, leg or foot/heel pain (e.g., Oxford Hip Score 30) 
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Table 1 
Chronic Pain Management Platform: Pain Locations and Validated Instruments for Assessing Pain and Functional Status 
 
Pain Location Instrument  Score 
Head Pain Migraine Disability Assessment Score 
(MIDAS)  31 
Grade 1: Little or no disability (score 0 – 5) 
Grade 2. Mild disability (score 6 – 10) 
Grade 3: Moderate disability (score 11 – 20) 
Grade 4: Severe disability (score 21+)  
Orofacial Pain Manchester Orofacial Pain and Disability 
Scale 32     
Physical Disability (score 0-14; 0 = least disability) 
Psychosocial Disability (score 0-38; 0 = least 
disability) 
Aggregate (score 0 – 52) 
Neck or Cervical Pain Copenhagen Neck Functional Disability 
Scale 33    
Aggregate score (0 – 30; 0 = no real complaints to 
30 = real disability) 
Shoulder Pain Shoulder Pain and Disability Index 
(SPADI)34 
Aggregate score, total pain score and total 
disability score each as a percentage. Minimum 
detectable change 13 points (90% confidence) 
Elbow Pain Patient-Rated Elbow Evaluation (PREE)35 Pain subscale and Function subscales with total 
score with pain and functional problems weighted 
equally on a scale of 100 (0 = no disability) 
Wrist or Hand Pain  Patient- Rated Wrist Hand Evaluation 
(PRWHE)36  
Pain score (0=50), Function score (0-50) and total 
score (0= best score; 100 = worst score) 
Mid-back or Thoracic Pain Roland Morris Disability Scale 37 38      Score 0 – 24 (score ≥ poor outcome)  
Lower-back or Lumbar Pain Roland Morris Disability Scale Score 0 – 24; (score ≥ poor outcome) 
Hip Pain Items only No validated aggregate score or subscales 
Lower Abdominal Pain 
(Males) 
NIH-CPSI Abdominal Pain 
Questionnaire39 
Pain: score 0 – 21 (0 = least pain) 
Urinary Symptoms: score 0 – 10 (0 = no problem) 
Quality of Life: score 0 – 12 (0 = no impact) 
Lower Abdominal Pain 
(Females) 
NIH-CPSI Abdominal Pain Questionnaire  Pain: score 0 – 21 (0 = least pain) 
Urinary Symptoms: score 0 – 10 (0 = no problem) 
Quality of Life: score 0 - 12 ( 0 = no impact) 
Knee Pain International Knee Documentation 
Committee (IKDC) Questionnaire: 2000 
Subjective Knee Evaluation Form40 
Summing score (max 87) to give percentage. 
Score 100 no limitations.  
Leg Pain Items only No validated aggregate score or subscales 
Foot or Heel Pain Items only No validated aggregate score or subscales 
 
 
Attitudes and Risks in Medication Utilization 
A particular focus of the CPMR is not only on the outcomes 
experienced by patients treated with opioid medications, but on 
patient experience with medications, their attitudes to  pain 
medications, the likelihood of medication abuse and a self-
report of actual ‘abuse’ reported by patients. The CPMR 
captures, in the initial patient report, medication utilization, 
patient experience with opioids (to include prior opioid 
prescriptions and opioid use within the past 30 days), patient 
attitudes to pain medications (see below) and an assessment of 
likelihood of aberrant medication behavior. In the follow-up 
reports by patients (see below) a series of questions on aberrant 
medication use behavior is presented to capture the extent of 
such behaviors, The categorization of opioids for self-reporting 
is presented in Table 2. More precise details on medication 
utilization can be generated in the provider/patient registry 
version from the physician office report to include brand name 
(NDC code), dosage, number of tablets and days supplied (see 
below). This provides a more accurate picture of medication use 
as opposed to asking patients to self-report medication use. 
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Table 2 
Chronic Pain Management Platform: Opioid Categorization  
 
Opioid Category 
Oxycodone (e.g., Oxycontin, Roxicodone, Oxecta, Percocet, Percodan, Xtampza, Targiniq, Troxyca, Roxybond) 
Hydrocodone (e.g., Anexia, Hycet, Vicodin, Lorcet, Lortab, Vicodin, Zydone, Hyslinga, Vantrela)  
Morphine (e.g., MS Contin, Oramorph SR, Avinza, Arymo, Morphabond, Embeda) 
Hydromorphone (e.g., Dilaudid, Exalgo, Palladone) 
Fentanyl (e.g. Actiq, Fentora, Duragesic, Subsys, Sublimaze, Abstral, Onsolis, Lazanda) 
Codeine (e.g., Tylenol with codeine) 
Methadone (e.g., Dolophine, Methadose) 
Meperidene (e.g., Demerol) 
Oxymorphone (e.g., Opana) 
Tramadol (e.g., ConZip, Ultram, Ryzolt) 
Tramadol (e.g., ConZip, Ultram, Ryzolt) 
Buprenorphine (e.g., Subutex, Buprenex, Butrans, and Probuphine and Buprenorphine/Naloxone combinations 
Suboxone, Zubsolv,  Bunavail) 
 
Note: Self-reported for (i) any previous prescription (no time limit) and (ii) use in last 30 days. 
 
A number of validated instruments have been developed to 
assess patients’ attitude to medications, to include their beliefs 
and concerns, as these have the potential to impact medication 
choice, utilization, adherence and persistence. In 2006 
McCracken el al reported on the development of a 78-item Pain 
Medication Attitude Questionnaire (PMAQ) that addressed 
seven areas of patient concern: addiction, perceived need, 
unfavorable scrutiny by others, adverse side effects, tolerance, 
mistrust in the prescribing doctor and withdrawal 41. More 
recently Elander et al have proposed a short form 14-item 
version (PMAQ-14) of the original questionnaire, capturing from 
the original 2 items from each of the seven PMAQ scales those 
that retained the content of the original scales 42 . Confirmatory 
factor analysis demonstrated that the PMAQ-14 retained the 
original 7-factor structure with correlation analysis 
demonstrating that it retained the validity of the original 
constructs. The PMAQ-14 was chosen for the CPMR.  
 
As well as capturing attitudes to medications, the CPMR also 
addresses the question of the risk for prospective medication 
aberrant behavior. Once again, a number of risk assessment 
instruments have been proposed. These include the Pain 
Medication Questionnaire (PMQ), the Screener and Opioid 
Assessment for Patients with Pain - Revised (SOAPP-R; 5, 14 and 
24 item versions), the Opioid Risk Tool (ORT) and, most recently, 
the Brief Risk Questionnaire (BRQ) 43 44 45 46.  
 
The BRQ was chosen in preference to other risk assessment 
instruments, specifically the Opioid Risk Tool (ORT) and the 
Screener and Opioid Assessment for Patients with Pain – Revised 
(SOAPP-R), because, on evidence available it is overall the most 
accurate with a sensitivity of 80% and a specificity of 41%. 
Sensitivity in this context is the ability to identify those patients 
who later were observed to engage in opioid or medication 
misuse. The sensitivity of the BRQ, which is best seen not as            
a 12-item overall assessment of risk but as an evaluation of          
12 areas of risk, also compared favorably in a head-to-head 
comparison with the structured clinical Brief Risk Interview    
(BRI) 47. 
  
Although outside the scope of the registry at this time, as it 
involves both patient reporting and clinical assessment, the BRI 
is an accepted ‘gold standard’ for the various PRO instruments 
with, in this comparison, a sensitivity of 79% and specificity of 
51%. The sensitivity of the ORT instrument was found to be 32% 
with a corresponding specificity of 82%; the corresponding 
figures for the SOAPP-R instrument were 33% and 77%. While 
the specificity of the ORT and SOAPP-R instruments was higher, 
it is worth noting that the ability to detect patients unlikely to 
engage in medication misuse should be set against the higher 
costs to the patient and society of misuse so that, on balance, a 
false positive understatement of the likelihood of appropriate 
behavior is acceptable.  
 
Symptoms and Co-morbidities 
The final section of the initial patient questionnaire provides a 
baseline status for five comorbidities or symptoms associated 
with chronic pain: fatigue, depression, anxiety, constipation and 
sleep. All the instruments used have been validated. The details 
are given in Table 3. These are not the only comorbidities and 
adverse events (side effects) that are captured by the CPMR. The 
physician practice (see below) is asked to report on other 
diagnosed comorbidities (ICD-10-CM codes) and adverse events 
(ICD-10-CM codes). 
 
One reason for selecting these comorbidities and symptoms 
(e.g., presence of constipation with opioid use and its treatment) 
is that it is important, not only to attempt to assess the impact 
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of treatment interventions on pain and functional status but the 
association with the alleviation of fatigue, depression anxiety 
and sleep.  Constipation is, of course, a well- documented side 
effect of opioid medications and one that while it can be treated 
may impact the willingness to continue therapy  
 
Patient Follow-Up Visit Reports 
For all subsequent visits to the physician practice over the course 
of treatment, patients are requested on-line to complete a 
Patient Follow-up Visit Report prior to their practice visit. This  
can  be  programmed  to  ask  patients  to    complete follow-up 
reports even if they do not attend the practice; the schedule to 
be determined by the treating physician. The follow-up report 
captures all information covered in the initial visit report with 
the exception of: (i) socio-demographic characteristics;  (ii) prior 
chronic pain experience and the likelihood of continuing chronic 
pain; and (iii) attitude to medications and the risk of aberrant 
medication behavior. Additional information requested in the 
self-reports are: (i) pain medication ADRBs (aberrant drug-
related behaviors) in the past 30 days or since last practice visit; 
and (ii) patient perception of change applying the PGIC 
instrument.  
 
  
 
 
Table 3 
Chronic Pain Management Platform: Symptom and Co-Morbidity Instruments 
 
Symptom or Comorbidity Comorbidities and Symptoms Score 
Fatigue  Fatigue Severity Scale 48 49   Single score as average of 9 items; presence 
of fatigue ≥ 4. Note: mean 2.3 (SD +/- 0.7 in 
normal healthy adults) 
Depression PHQ-9 Depression Scale 50   Score range 0 – 27 
Minimal Depression (score 0 – 4) 
Mild Depression (score 5 – 9) 
Moderate Depression (score 10 – 14) 
Moderately severe depression (score 15 – 19) 
Severe Depression (score 20+) 
Anxiety GAD-7 Anxiety Scale 51   Score range 0-28 
None or very mild anxiety (score 0 – 4) 
Mild anxiety (score 5 – 9) 
Moderate anxiety (10-15) 
Severe anxiety (16+)  
Constipation PAC-SYM Questionnaire 52   Score averaged over 11 items (range 0 – 4) 
Average or mild constipation (score 0 – 0.9) 
Moderate constipation (score 1.0 – 2.9 
Severe or very severe constipation (Score 
3.0+) 
Sleep RAND Sleep Report and 
Questionnaire 53   
Sleep Experience (last 2 weeks): Time taken 
to fall asleep, hours of sleep. RAND Sleep 
(score 0 – 50; 0 = no problems to 50 extreme 
problems) 
 
There are a number of instruments to choose from when it 
comes to identifying those patients with chronic pain taking 
opioids (or other medications) who have indications of current  
opioid risk and aberrant drug-related behaviors. As the CPMR is 
designed,  not  for  one-off  measures of  ADRBs, but for regular  
patient assessments, the instrument should ideally be one that  
interrogates patients for behavior since their last visit or within 
a relatively short time frame. Given this constraint, the 
Prescription Drug Use Questionnaire – patient version (PDUQp)  
 
 
 
is clearly unsuitable as the question time frames are either open 
ended or refer to the previous 6 months  54. The PDUQp is also 
unacceptable given the possibility of respondent fatigue given 
the 31 items that comprise the questionnaire.  
 
Another possible candidate is a modified shorter version of the 
PMQ comprising 10 items from the PMQ and a further 5 items 
covering selling, forging prescriptions, internet sources and 
using medications involving crushing and snorting 55. 
Consideration was also given to utilizing the Current Opioid 
Misuse Measure (COMM)56.  This is a 17 item validated measure 
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to identify patients with chronic pain who have indicators of 
current ADRBs. The COMM utilizes Likert scales (0 – 4) with a 
cut-off score of 9 points. However, to avoid possible conflicts as 
the COMM is already used with the SOAPP-R as an on-line 
commercial product tool for assessing opioid behavior, it was 
decided to generate a shorter item set (to minimize respondent 
fatigue) which covered the current aberrant behaviors 
commonly identified in these various instruments with a yes/no 
response. No attempt was made to provide an item response 
score to try to evaluate the ‘severity’ of the aberrant behavior. 
That is left to the treating physician.  
 
The items are: 
• In the past 30 days or since your last visit to this 
practice have you lost or misplaced your pain 
medication and had to ask for a replacement? 
• In the past 30 days or since your last visit to this 
practice have you sold any of your pain medication? 
• In the past 30 days or since your last visit to this 
practice are there days when you have taken more of 
your pain medication than prescribed? 
• In the past 30 days or since your last visit to this 
practice have family members or friends commented 
on how you were dealing with you pain medication? 
• In the past 30 days or since your last visit to this 
practice have you forged a prescription in order to 
obtain pain medication? 
• In the past 30 days or since your last visit to this 
practice have family members or friends obtained pain 
medication for you (e.g., from their physicians)? 
• In the past 30 days or since your last visit to this 
practice have you tried to supplement your pain 
medication(s) with other drugs to help your pain 
medication work better? 
• In the past 30 days or since your last visit to this 
practice have you obtained pain medications from the 
internet or other non-medical source?  
• In the past 30 days or since your last visit to this 
practice have you used your pain medication in a form 
other than how it was prescribed (e.g., crushed, 
snorted, injected)? 
• In the past 30 days or since your last visit to this 
practice have you visited another physician, including 
urgent care, to obtain pain medication? 
• In the past 30 days or since your last visit to this 
practice have you visited the emergency room to 
obtain pain medication? 
• In the past 30 days or since your last visit to this 
practice have you taken pain medications belonging to 
someone else? 
• In the past 30 days or since your last visit to this 
practice have you used your pain medications for 
conditions other than your pain (e.g., to help you 
sleep, to relieve stress)? 
Patient Satisfaction Initial Visit Report 
Following the first practice visit, the patient is asked to complete 
on-line an Initial Patient Satisfaction and Pain Management 
Assessment Report. For all subsequent visits the patient only 
completes the patient satisfaction with care component. This 
covers: 
• Provider: satisfaction with care provided 
(thoroughness, time spent, overall quality of care) 
• Other Staff: satisfaction with care provided (reception 
staff, courtesy) 
• Practice access: satisfaction with access provided (\ 
contacting office, waiting in office, parking) 
Where, in each case, responses are on a five point scale: 
excellent, good, just satisfactory, fair or poor.  
 
In addition, the patient completes after the initial visit as part of 
the satisfaction report a series of questions on the extent to 
which a pain management plan has been provided and whether 
specific issues (e.g., fatigue, anxiety, depression, sleep) have 
been addressed. The patient is told that: A pain management 
plan is a proposal for how your pain problem is to be addressed; 
it might involve a proposal for a management team involving 
other specialist providers and nursing support, treatment 
options and possible use of pharmaceuticals, a timeline for 
treatment and the outcomes sought. You might also be advised 
on the potential for over dosing and abuse of prescription pain 
medications.  
 
The specific questions are: 
• Did your provider discuss and agree a pain 
management plan with you? 
• Did you provider review your past medication use in 
the treatment of your pain condition? 
• Did your provider discuss the benefits and risks of the 
use of opioids in the treatment of your pain? 
• Did your provider discuss the benefits and risks of 
prescribing ‘risk abuse’ opioid formulations? 
• Did your provider discuss the possibility of non-opioid 
drug formulations in the treatment of your pain? 
• Did your provider discuss how long you might be on 
pain medication? 
• Did your provider discuss what non-pharmacological 
options there might be for your pain condition (e.g., 
surgery, acupuncture)? 
• Did your provider discuss how any comorbid disease 
states that you have (e.g., cardiovascular disease, 
diabetes) might impact your pain treatment? 
• Did your provider discuss the possible involvement of 
other health professionals in your treatment? 
• Did your provider assess and recommend treatment 
for fatigue? 
• Did your provider assess and recommend treatment 
for anxiety? 
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• Did your provider assess and recommend treatment 
for depression? 
• Did your provider assess and recommend treatment 
for constipation? 
• Did your provider discuss what the side effects of your 
treatment might be? 
• If you are not at work, did you discuss with your 
provider the possibility of returning to work? 
 
 
Patient Summary Reports to the Physician Practice 
There are two patient response summary reports prepared 
automatically by the CPMR and transmitted to the physician 
practice for each patient prior to the patient’s encounter with 
the provider. These are 
• Patient Initial Visit Summary Report 
• Patient Follow-up Visit Summary Report 
 
All summary reports provide individual item scores as well as 
summary scores for validated instruments. The  summary report 
to the physician or practice includes: 
• Demographic and sociodemographic responses 
• Present and previous health status 
• Present pain experience (pain intensity) 
• Pain experience and impact in last 6 months 
• Chronic Graded Pain Scale  
• Likelihood scores for continuing chronic pain 
• Pain location(s) 
• Pain status and functionality scores by pain location 
• Possibility of neuropathic pain/fibromyalgia 
• Prescription opioid history 
• Opioid use in past 30 days 
• Views on pain medications (scores for addiction, need, 
scrutiny, side effects, tolerance, mistrust of doctors and 
withdrawal concerns) 
• Aberrant opioid risk assessment 
• Fatigue score 
• Depression score 
• Anxiety score 
• Constipation score 
• Sleep experience (last two weeks) and sleep problems 
score 
If the provider is linked to a medical marijuana dispensary for the 
patient, then following each dispensary visit the provider will be 
sent: 
• Cannabis administration form and dosing 
• Titration (if necessary) 
• Pain intensity and pain functional status by location 
change over baseline  
• Comorbid status and change over baseline 
• PGIC 
• Change in other conditions if reported (severe nausea, 
persistent muscle spasms, seizures) 
 
The Patient Follow-up Visit Summary Reports provide a 
summary of current status versus initial or baseline status over 
the course of treatment for: 
• Employment status  
• Overall health 
• Pain experience 
• Pain status and functionality score by pain location 
• Item checklist for  aberrant medication behaviors 
• Fatigue 
• Depression 
• Anxiety 
• Constipation 
• Sleep experience 
• Patients’ Global Impression of Change (PGIC) 
Each Patient Follow-up Visit Summary report also includes an 
item checklist for aberrant medication behaviors (see above). 
To assist the physician assessing the statistical and clinical 
significance of changes in the various scores, notes are included 
in the summary report to the physician with estimates of (i) 
minimum detectable change (MDC) and (ii) minimum clinically 
important change (MCID). The MDC is a statistical estimate of 
the smallest amount of change that can be detected by a 
measure that corresponds to a noticeable change that is not 
attributable to measurement error (estimated at 90% or 95% 
confidence intervals). The MDIC takes the physicians’ 
perspective in judging whether a change is clinically significant 
or, put differently, the minimum amount of change that a 
physician judges is required for a patient to feel a difference. The 
patient may not, of course, concur in this assessment of change. 
For this reason the PGIC scale is also reported.  
 
Patient and Provider CPMR Version 
The provider version of the CPMR requires the practice to report 
on the individual patient. Subsequent to or during each practice 
encounter with the patient, the practice is asked to submit on-
line a Physician Office Visit Report. There is a separate report for 
the initial patient visit, the Physician Office Initial Visit Report 
and a standard report for all follow-up visits, the Physician Office 
Follow-up Visit Report. 
 
Physician Office Visit Reports 
The Physician Office Initial Visit Report and the Physician Office 
Follow-up Visit Report are designed to capture a range of 
information that has been collected by the practice as part of the 
patient encounter. Specific data elements are captured from 
those reported on the CMS 1500 form or its EMR equivalent 
(paper or electronic) in respect of the ICD-10-CM diagnosis 
codes and CPT codes. These are supported by questions on: (i) 
pain evaluation; (ii) medication utilization; (iii) adverse events; 
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(iv) opioid experience and options; and (v) discontinuation of 
therapy.  
 
The pain evaluation questions ask, first, whether the pain is the 
result of trauma or injury (e.g., personal injury at home, motor 
vehicle accident, military service). If this is not the case, the 
practice is then asked to detail whether it was caused by surgery 
(which may be related to trauma or injury) with the type of 
surgery to be detailed by date of surgery, CPT procedure code 
and a brief description. If the pain is not related to trauma, injury 
or surgery, the practice is then asked to report on whether it is 
related to a comorbid condition (e.g., diabetic neuropathy) 
defined by the appropriate ICD-10-CM code. 
 
The practice is asked to detail all prescription medications 
currently reported.  Comparing these over time within the 
registry framework will give a profile of use, switching, dosage 
change and discontinuation. . For each medication the practice 
is asked to list: generic and brand name, dosage, number of 
tablets/pills per day, days supplied, whether the medication is 
being titrated or is a rescue medication, together with the NDC 
code. 
 
Apart from prescription medications, the physician’s office is 
also asked to report if the patient has been recommended for 
medical marijuana. If the patient is reported as having met 
certification requirements, then the office is asked to report the 
THC/CBD (or CBD) formulation and mode of administration.  
 
It is important that in reporting ICD-10-CM diagnoses that the 
entries capture both the primary diagnosis as well as any 
supplementaryor comorbid diagnoses (e.g., diabetes, 
cardiovascular disease, depression, anxiety) using billable codes. 
Practices are asked to be as precise as possible in indicating the 
type of pain and to avoid the use of non-specific or nor billable 
pain codes. Importantly, the ICD-10-CM codes reported should 
match the pain locations identified by the patient.  
 
As an example, as functional status often refers to a joint and 
the presence of joint pain, the use of only billable codes would 
exclude the use of M25.5 Pain Joint (non-billable) or at a lower 
level M25.51 Pain in Shoulder (non-billable) but report more 
specifically the billable code M25.511 Pain in Right Shoulder. 
Although a billable code, the code M25.50 Pain in Unspecified 
Joint should not be used. This level of detail does not apply, for 
example to M54.6 Pain in Thoracic Spine which is a billable. 
 
The practice is then asked to detail whether or not an office 
procedure was performed. A list of interventional procedures is 
given with the practice asked to check off the particular 
intervention, with a write in response for a non-0listed 
intervention. The practice is not asked to report CPT/HCPS 
codes. Future versions of the CPMR might consider these to give 
more granularity but at a possible added burden on the practice. 
The practice is asked also to report adverse events. It is up to the 
practice to determine the severity and appropriateness of 
reporting. When these events are reported the appropriate ICD-
10-CM code should be used. It should be noted that these may 
duplicate billable ICD-10-CM codes that may already have been 
entered (e.g., K59.00 Constipation, unspecified, K59.04 Chronic 
idiopathic constipation, K50.09 other constipation, R11.2 
Nausea with vomiting, unspecified). 
 
Given the likelihood of significant comorbidities accompanying a 
diagnosis of chronic pain, the practice is also asked whether or 
not referrals have been made for assessment/treatment by a 
specialist. The items of interest are (i) specialty to which the 
patient has been referred and (ii) the reason for referral. 
Importantly, the provider is also asked to report whether the 
patient has been recommended or certified for medical 
marijuana. If certification has occurred, the provider is asked to 
detail the dispensary providing the access to botanical cannabis. 
This provides the link for the dispensary to submit visit reports 
on the patient’s status in respect of chronic pain and any 
associated conditions (e.g., severe nausea). If the dispensary has 
adopted the associated registry platform, the outcomes 
reported will be consistent with those tracked by the provider 
practice both prior to the recommendation for medical 
marijuana and any ongoing interaction with the provider if the 
cannabis dispensed, for example, is part of a chronic pain 
polytherapy regimen.  
 
The physician’s office is asked to report in detail on the patient’s 
experience with opioids and efforts by the practice to reduce 
exposure to opioids. The key data elements requested are (i) 
urine testing; (ii) presence of an opioid agreement; (iii) referral 
to a methadone/buprenorphine treatment program; (iv) 
tapering/discontinuation of opioid therapy; and (v) offers of 
alternative pain management interventions.  
 
Under (iv) the practice is asked to report the reason(s) for 
tapering/discontinuation of opioid therapy. The options are:  
• Failure to show sufficient analgesia 
• Failure to show functional improvement 
• Excessive dosing to achieve pain management targets 
• Presence of significant clinical risk factors (e.g., sleep 
apnea) 
• Impact of medication side/adverse effects 
• Patient request 
• Patient’s family request 
• Opioid aberrant behavior 
• Non-opioid substance use aberrant behavior 
• Failure to agree to adopting a non-opioid pain 
management plan  
As the CPMR also tracks botanical cannabis use (including, it 
should be noted, TCH/CBD combinations and non-hemp derived 
CBD products) the questions to the opioid 
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tapering/discontinuation can be applied to both hemp-derived 
and non-hemp marijuana products. 
Finally the practice is asked to report on the scheduling of the 
next appointment and, where a future appointment has not 
been scheduled the reason why it has not been scheduled. The 
practice is asked, from a check list, to give the reason(s) for non-
scheduling. The options include satisfactory resolution of pain 
and functional symptom, patient decision to cease treatment 
even if symptoms not resolved, unacceptable side effects and 
moving to another practice. 
 
Practice Standardized Patient Reports 
 
The CPMR, in the patient/provider version, generates at the end 
of each month seven practice summary reports. Modified 
versions are available for the patient only CPMR version. These 
reports are: 
(i) Monthly Practice Profile Initial Encounter Report  
(ii) Monthly Practice Profile Initial Pain Intensity and 
Functional Status Report 
(iii) Monthly Initial Encounter Satisfaction Profile   
(iv) Monthly Pain Location Continuing Patients Outcomes 
Report 
(v) Monthly Procedures Continuing Patients Outcomes 
Report 
(vi) Monthly Continuing Patients Pain Location and Opioid 
Outcomes Report 
(vii) Monthly Continuing Patients Opioid Outcomes Report 
 
Monthly Practice Profile Initial Encounter Report 
This report details for all patients who were initially enrolled in 
the CPMR in that month the key data elements reported in the 
Patient Initial Visit Report and the Patient Initial Visit Summary 
Report. It excludes functional status by pain location which is 
detailed in the second monthly practice profile report (below). 
 
Monthly Practice Profile Initial Pain Intensity and Functional 
Status Report 
The report focuses on the pain locations reported by patients at 
their initial visit and gives a summary across all patients the 
average pain intensity and functional status reported. This is the 
baseline for subsequent assessments of the impact of therapy 
interventions by pain location.  
 
Monthly Pain Location Outcomes Report 
The monthly pain location outcomes report is for continuing 
patients and can be modified for time elapsed since initial 
therapy intervention. Standard timeframes are 90, 180 and 270 
days.  
 
 
 
Monthly Initial Encounter Satisfaction Profile 
For each satisfaction with care item the number of patients and 
the average score (range 0 – 4). For initial patients there is a 
further list of items that a provider might have considered as an 
element of a pain management plan. The numbers of responses 
to each question are given with percentage of total responses. 
 
Monthly Pain Location Continuing Patients Outcomes Report 
This report captures at the end of each month the outcomes 
reported by patients who have maintained adherence to their 
initial pharmacotherapy, including dosage adjustments and 
supplemental pharmacotherapy. Initial number of patients are 
recorded, the number who have discontinued therapy, the 
number who have received modified pharmacotherapy and 
their responses to the PGIC scale, This gives a distribution of 
responses from ‘no change’ to ‘a great deal better’. The time 
frame for the response is adjusted to 90, 180 and 270 days, 
Responses are given for each pain location treated. 
 
Monthly Procedures Continuing Patients Outcomes Report 
This report is identical to the previous report in the distribution 
of PGIC responses by the type of interventional procedure. 
Patients are identified if they have received supplemental 
pharmacotherapy with a similar timeframe options for 
reporting. 
 
Monthly Continuing Patients Pain Location and Opioid Report 
This report is identical to the first pharmacotherapy report while 
restricted to patients who have taken opioids. 
 
Monthly Continuing Patients Opioid Outcomes Report 
The focus of this report is on the medium to long-term response 
to opioids in chronic pain. The table details for each of the opioid 
classes the number of patients initiated to that class of opioids, 
the number who have dropped out from therapy and the 
number receiving modified or supplementary pharmacotherapy. 
For continuing patients at 90, 180 and 270 days the response to 
therapy is captured by the PGIC scale.  
 
The point to note is that these standard monthly reports provide 
a framework for a possible more in-depth assessment of the 
response to therapy by target patient groups. In the case of 
those initiated to an opioid therapy (e.g., a recently introduced 
abuse deterrent formulation) the practice might be interested in 
the response to individual products within an opioid class and 
those patients who, at 90 days, report no change in their 
response to the intervention. This could be supplanted by 
reasons for opioid therapy discontinuation and the possible 
impact of medication abuse behaviors. 
 
Once a pain location is selected, the CPMR can specify the 
pharmacology (e.g., Oxycodone or Xtampza ER as a specific 
product) or intervention used (e.g., Genicular Nerve Ablation) 
with tables created to compare various interventions (e.g., 
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comparing abuse deterrent opioid formulations). Alternatively, 
the CPMR can generate tables for all patients initially treated for 
lower back pain without further detail for individual 
interventions. Finally, the CPMR can specify the time since initial 
therapy (initial visit date). The report will capture all patients in 
the CPMR that meet these criteria and seek their input to table 
creation.  
 
Meeting CPMR Reporting Requirements 
A perennial concern in treatment practice is the question of the 
resources available to streamline workflow as well as 
endeavoring to meet demands placed on the practice for 
meeting quality metrics and, in the case of the CPMR, meeting 
the reporting standards. In the last case the resource demands 
are (i) allocating time to evaluating and reporting on the patient 
in completing the post-visit reports and (ii) assigning 
responsibilities for evaluating and reporting on the standard 
monthly reports from the CPMR as well as generating 
customized reports for the practice. 
 
Understandably, physician practices are reluctant to introduce 
reporting standards where a practice is already overworked in 
terms of the time allocated to patient assessment and the 
additional resources that may be required to evaluate practice 
performance in the treatment of chronic pain. In short, where 
practice resources are scarce and overstretched, there has to be 
an incentive for practices to adopt quality metrics and engage in 
a more comprehensive assessment of practice performance. 
This is of particular importance in the management of chronic 
pain where the societal costs of opioid misuse and abuse are 
substantial with physician practices, in particular specialized 
pain practices, being asked to shoulder greater responsibilities. 
 
It is not the intention to offer advice on the possibility and 
practicability of attracting additional financial resources to the 
practice through the various elements (e.g., pain and functional 
status assessments, opioid risk and abuse evaluations) captured 
on an ongoing basis by the CPMR. Even so, it is worth noting 
potential opportunities to augment practice resources, including 
covering the operational costs of the CPMR and generating 
additional revenue to support ongoing pain management. 
 
One example is the potential for supplementing practice 
revenue through meeting the various requirements of the Merit 
Based Incentive Payment System (MIPS) score: quality measures 
(2018: 50%), advancing care information (2018: 25%), 
improvement activities (2018: 15%) and resource use (2018: 
10%, calculated by CMS). In the case of quality measures, the 
CPMR captures a substantial number of the proposed metrics. 
These include metrics for functional status change (e.g., ID 182, 
ID 217, ID 218, ID 219, ID 220, ID 221, ID 222, ID223) as well as 
more general metrics such as ID 131 Pain Assessment and 
Follow-up, metrics relating to opioid assessment and use (ID 
412, ID 414, ID 408) and those for depression screening and 
follow up (ID370, ID 371, ID 411) 57. 
In the case of advancing care information the CPMR supports 
reporting on the baseline performance measures (e.g., health 
information exchange) with additional points possible for 
reporting data to a platform, advance care planning and 
promoting the use of patient-reported outcomes tools 58. 
 
Finally, under improvement activities the CPMR captures a 
number that may qualify. These include Activity 1A_EPA_2 
Collection and use of patient experience and satisfaction data on 
access,  Activity 1A_PM_14 Implementation of methodologies 
for improvements in longitudinal care management in high risk 
patients and activity 1A_BE_4 Engagement of patients through 
implementation of improvements in patient portal 59.   
 
Apart from MIPS, there is the possibility of utilizing CPT billable 
codes to capture the data and information elements covered by 
the CPMR. Before considering this opportunity advice should be 
sought from coding and billing experts. It is not the role of this 
description of the CPMR to offer advice or to encourage this 
option. Exercising this option is at the discretion of the physician 
practice. Reimbursement rates may vary depending on practice 
location and insurance cover, with commercial insurers 
reimbursing at different rates from Medicare and Medicaid, 
including the number of visits made to the practice with codes 
applicable and potentially reimbursed at each visit. These 
billable codes potentially include, to give a few examples, CPT 
96127 for scoring and documenting brief emotional and 
behavioral assessments/screening codes  (four per patient visit); 
CPT 96103 computer administered psychological testing: CPT 
99490 chronic care management, together with the more time 
consuming CPT 99487 and CPT 99489 codes; CPT96160 for 
health risk assessment; and G-codes for alcohol and/or 
substance abuse screening and intervention and associated G 
codes for functioning and physical therapy. Although not pain 
management specific, there are a range of evaluation and 
management CPT codes that should be considered with the 
information generated by the CPMR. These cover: (i) new 
patient visit (CPT 99201 to 99205) and (ii) established patient 
visit CPT 99211 to 99215). For a more comprehensive approach 
to coding in pain management there are the web site and code 
books of the American Academy of Pain Management 60. 
 
Conclusions 
Practice based registries with inputs from both patients and 
providers are not new. What sets the CPMR apart is the focus on 
the management of chronic pain with real-time feedback to both 
patients and providers. The treatment of chronic pain in the US 
is a particular concern: opioids are abused and physicians have 
little guidance on the benefits and risks in the medium and long 
term. While they may be reluctant to prescribe opioids, they are 
also faced with a dearth of alternatives. Botanical cannabis may 
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be one solution, but as in the case of opioids, evidence is 
required to support decision making.  
 
Where resources are scarce, the application of validated PROs 
and other measures of response to therapy can potentially 
support provider claims for additional resources. These may be 
through meeting quality metric standards as well as from billable 
codes for reimbursement. Whether these possibilities are acted 
on is a decision for the practice. The point is, however, that they 
provide a basis for additional practice resources to enhance the 
process and duty of care in chronic pain.  
 
A final point to note is the proposed platform can be 
implemented in stages. An initial installation could be in terms 
of just patient reporting with reports sent to the practice at 
scheduled visits. This version would still support billable codes 
as these are based on the patient reported section of the 
complete platform. A practice may then decide to implement 
provider reporting as well as patient reporting. This would 
include patterns of adherence, reasons given by the provider for 
therapy switching and therapy termination.  
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